What is the optimal radiotherapy utilization rate for lung cancer?-a systematic review
- PMID: 31673521
- PMCID: PMC6795583
- DOI: 10.21037/tlcr.2019.08.12
What is the optimal radiotherapy utilization rate for lung cancer?-a systematic review
Abstract
Lung cancer is a major cause of morbidity and mortality globally. Although radiotherapy (RT) may be beneficial in the radical and/or palliative management of many lung cancer patients, it is underutilized worldwide. Population-level development of RT resources requires estimates of optimal radiotherapy utilization rates (ORUR) and actual radiotherapy utilization rate (ARUR). A systematic review of PubMed database for English-language articles from January 2009 to January 2019 was performed. Keywords included utilization, underutilization, demand, epidemiologic, benchmark, RT and cancer. Data abstracted included: study population, diagnosis, stage, year of diagnosis, timing of RT, intent of RT, ARUR, and ORUR. Eligible studies provided ARUR or ORUR for lung cancer, small cell lung cancer (SCLC), or non-small cell lung cancer (NSCLC). Included ARUR were based on at least 1,000 patients who were diagnosed or treated in 2009 or later. Included ORUR were based on evidence review or ARUR in 2009 or later. The initial search strategy yielded 1,627 unique abstracts. After review, 105 articles were determined appropriate for full-text review. From these, a final set of 21 articles met all inclusion criteria. In eight papers, ORUR was estimated. Estimated lifetime ORUR ranged from 61% to 82%. Methods for estimation included the evidence-based guideline model, Malthus model, and criterion-based benchmarking (CBB) model. The majority of estimates (6/8) used the evidence-based guideline model. Fifteen papers provided ARUR on lung cancer, inclusive of SCLC and NSCLC. ARUR within 9 months to 1 year of diagnosis ranged from 39% to 46%. Lifetime ARUR was an estimated 52% in Ontario, Canada. Palliative intent ARUR ranged from 12% in Central Poland to 46% in Ontario, Canada. RT is underutilized for lung cancer globally, and there is wide geographical variation in the level of underutilization.
Keywords: Lung neoplasms; global health; radiotherapy (RT); systematic review.
2019 Translational Lung Cancer Research. All rights reserved.
Conflict of interest statement
Conflicts of Interest: Dr. Louie has received honoraria from Varian Medical Systems Inc. and AstraZeneca. The other authors have no conflicts of interest to declare.
Figures
Similar articles
-
Colorectal cancer radiotherapy utilization rate in a low-middle income country - a multicenter study in Indonesia.Contemp Oncol (Pozn). 2025;29(1):113-122. doi: 10.5114/wo.2025.149236. Epub 2025 Apr 9. Contemp Oncol (Pozn). 2025. PMID: 40330449 Free PMC article.
-
Defining the need for radiotherapy for lung cancer in the general population: a criterion-based, benchmarking approach.Med Care. 2003 Sep;41(9):1074-85. doi: 10.1097/01.MLR.0000083742.29541.BC. Med Care. 2003. PMID: 12972847
-
Estimation of the optimal radiotherapy utilization rate for childhood neuroblastoma.Radiother Oncol. 2024 Aug;197:110343. doi: 10.1016/j.radonc.2024.110343. Epub 2024 May 26. Radiother Oncol. 2024. PMID: 38806114
-
Determining the need and utilization of radiotherapy in cancers of the breast, cervix, lung, prostate and rectum: A population level study.Radiother Oncol. 2017 Jan;122(1):152-158. doi: 10.1016/j.radonc.2016.12.006. Epub 2016 Dec 21. Radiother Oncol. 2017. PMID: 28012795
-
Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part II--carcinoma of the endometrium.Cancer. 2004 Aug 15;101(4):682-92. doi: 10.1002/cncr.20445. Cancer. 2004. PMID: 15305397 Review.
Cited by
-
Developing a prospective rapid-learning methodology to evaluate the survival impact of changing radiotherapy practice to include a new heart dose limit for patients with lung cancer in a UK specialist cancer centre (RAPID-RT): a protocol.BMJ Open. 2025 Aug 27;15(8):e105519. doi: 10.1136/bmjopen-2025-105519. BMJ Open. 2025. PMID: 40866065 Free PMC article.
-
Optimal and actual rates of Stereotactic Ablative Body Radiotherapy (SABR) utilisation for primary lung cancer in Australia.Clin Transl Radiat Oncol. 2022 Mar 5;34:7-14. doi: 10.1016/j.ctro.2022.03.001. eCollection 2022 May. Clin Transl Radiat Oncol. 2022. PMID: 35282142 Free PMC article.
-
Cobalt compensator-based IMRT device: A treatment planning study of head and neck cases.Phys Med. 2023 Feb;106:102526. doi: 10.1016/j.ejmp.2023.102526. Epub 2023 Jan 6. Phys Med. 2023. PMID: 36621080 Free PMC article.
-
Lipidome analyses reveal radiation induced remodeling of glycerophospholipid unsaturation in lung tumor.Front Immunol. 2024 Oct 24;15:1470269. doi: 10.3389/fimmu.2024.1470269. eCollection 2024. Front Immunol. 2024. PMID: 39512339 Free PMC article.
-
Dyspnea in patients with stage IV non-small cell lung cancer: a population-based analysis of disease burden and patterns of care.J Thorac Dis. 2023 Feb 28;15(2):494-506. doi: 10.21037/jtd-22-919. Epub 2023 Feb 20. J Thorac Dis. 2023. PMID: 36910044 Free PMC article.
References
-
- NCCN Guidelines Version 5. Non-Small Cell Lung Cancer [Internet] 2019 [cited 2019 Aug 3]. Available online: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
-
- NCCN Guidelines Version 1 2019 Small Cell Lung Cancer [Internet] 2019 [cited 2019 Aug 3]. Available online: https://www.nccn.org/professionals/physician_gls/pdf/sclc_blocks.pdf
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous